报价延迟最少15分钟:2026/04/21 19:27 EDT
盘后时段
|
||||
|
2.92 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.85
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.23/-0.39
|
|
企业价值
448.46M
|
| 资产负债 |
|
每股账面净值
0.87
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.25M
|
|
每股收益
0.00
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with apotential best-in-class mechanism of action. |
